Ignite Creation Date:
2025-12-24 @ 2:34 PM
Ignite Modification Date:
2026-01-02 @ 6:16 PM
Study NCT ID:
NCT02304159
Status:
COMPLETED
Last Update Posted:
2019-04-24
First Post:
2014-11-17
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
Sponsor:
Tarek I. Hassanein, M.D., FACP, FAG, AGAF
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
AI444284
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None